Dr. Spring on the Rationale for the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

Video

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Laura Spring, MD, attending physician, Medical Oncology, Massachusetts General Hospital, instructor of medicine, Harvard Medical School, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial (NCT03284957) in estrogen receptor (ER)–positive, HER2-negative advanced breast cancer.

The AMEERA-1 trial is evaluating the novel, oral selective ER degrader (SERD) amcenestrant as a single agent and in combination with other anti-cancer therapies, such as the CDK4/6 inhibitor palbociclib (Ibrance) in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, Spring says. The development of oral SERDs has been an area of research in this patient population and evaluating combination regimens with these agents is a logical next step to build upon single-agent activity.

During the 2021 San Antonio Breast Cancer Symposium, updated findings from AMEERA-1 were presented in a virtual poster. The results showed that giving 200 mg of amcenestrant in combination with the approved dose of palbociclib demonstrated a median progression-free survival of 14.7 months at a median follow-up of 14.8 months. The overall response rate with the combination was 32.4% and the clinical benefit rate was 73.5%.

Safety findings were consistent with previous results, suggesting that amcenestrant is well tolerated in this patient population and should be further evaluated in combination regimens, Spring concludes.

Related Videos
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD